Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel

Chimeric antigen receptor (CAR) T cell–related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with poor prognosis and a challenging diagnosis. The establishment of specific diagnosis criteria is essential, and the combination of several techniques for CAR T‐cell follow‐up, allows a more precise management of this complication.

[1]  W. Stock,et al.  Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature , 2021, Leukemia & lymphoma.

[2]  Michael R. Green,et al.  Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. , 2020, Blood advances.

[3]  R. Schneider,et al.  OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) , 2020 .

[4]  Michael M. Henry,et al.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. , 2020, The New England journal of medicine.

[5]  D. Maloney,et al.  Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. , 2020, Blood advances.

[6]  N. Berliner,et al.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. , 2019, Blood.

[7]  T. Staudinger,et al.  Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis , 2019, Journal of intensive care medicine.

[8]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[9]  P. La Rosée,et al.  Treatment of hemophagocytic lymphohistiocytosis in adults. , 2015, Hematology. American Society of Hematology. Education Program.

[10]  K. Nichols,et al.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies , 2015, Haematologica.

[11]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[12]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[13]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[14]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[15]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[16]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[17]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.